Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market